VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
- 30 June 2007
- journal article
- Published by Elsevier BV in Trends in Molecular Medicine
- Vol. 13 (6), 223-230
- https://doi.org/10.1016/j.molmed.2007.04.001
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancerNature Clinical Practice Oncology, 2007
- A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human bloodNature Protocols, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Angiogenesis in life, disease and medicineNature, 2005
- Common mechanisms of nerve and blood vessel wiringNature, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996